.Attributes Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires inclusion of patients with MASLD as well as dimension of liver outcomes in cardio-- renal-- metabolic trials, when records suggest mechanistically possible advantages as well as professional protection-- and also describes factors for trial layout and also regulatory commendation.